Skip to main content
SpringerLink
Log in

Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

With the objective of identifying new chemotherapeutic agents active against breast cancer, we administered the phase II agent deoxydoxorubicin (DxDx) to 25 patients who had received no prior chemotherapy for their metastatic breast cancer. A dose of 30–35 mg/M2 given at 3 week intervals resulted in a response rate of 12%. The patients were subsequently treated with a combination of 5-fluorouracil, methotrexate, vincristine, cyclophosphamide, and prednisone. A response rate of 38% was achieved with this combination as second line therapy. Toxicity of DxDx was predominately hematopoietic. One patient developed congestive heart failure. Median survival from onset of treatment with DxDx was 39 weeks. DxDx appears to be minimally active against metastatic breast cancer. Whether the administration of phase II agents as first line therapy offers an avantage in the overall management of metastatic cancer, needs further evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fabian CJ, Rasmussen S, Stephens R, Haut A, Smith F, Balcerzak S, Tranum B: Phase II evaluation of hexamethylmelamine in advanced breast cancer: A Southwest Oncology Group study. Cancer Treat Rep 63: 1359–1361, 1979

    PubMed  Google Scholar 

  2. Yap H-Y, Benjamin RS0 Blumenschein GR, Hortobagyi GN, Tashima CK, Buzdar AU, Bodey GP: Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep 63: 77–83, January 1979

    PubMed  Google Scholar 

  3. Martino S, Samal BA, Singhakowinta, A: PCNU in advanced breast cancer. Cancer Treat Rep 67: 305, 1983

    PubMed  Google Scholar 

  4. Knight WA, Von Hoff DD, Tranum B, O'Bryan R: Phase II trial of dihydroxyanthracenedione (DHAD, mitoxantrone) in breast cancer. A Southwest Oncology Group (SWOG) study. Proc ASCO (Abstract) 1: 87, April 25–27, 1982

    Google Scholar 

  5. Osborne CK, Von Hoff DD, Sandback J: Activity of bisantrene in a phase II study in advanced breast cancer. Proc ASCO (Abstract) 1: 87, April 25–27, 1982

    Google Scholar 

  6. Martino S, Samal BA, Singhakowinta A, Yoshida S, Mackenzie M, Jain J, Vaitkevicius VK: A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules. J Cancer Res Clin Oncol 108: 354–356, 1984

    PubMed  Google Scholar 

  7. Clinical Brochure for Deoxydoxorubicin. Division of Cancer Treatment, Natl Cancer Inst, 1983

  8. Monti E, Piccinini F, Favalli L, Villani F: Role of the fast-exchanging calcium compartment in the early cardiotoxicity of anthracycline analogs. Biochem Pharmcol 32: 3303–3306, 1983

    Google Scholar 

  9. Dickinson AC, Dejordy JO, Boutin MG, Teres D: Absence of generation of oxygen-containing free radicals with 4′-deoxydoxorubicin, a non-cardiotoxic anthracycline drug. Biochem Biophys Res Commun 125: 584–591, 1984

    PubMed  Google Scholar 

  10. Casazza AM, Savi G, Pratesi G, Di Marco A: Antitumor activity in mice of 4′-deoxydoxorubicin in comparison with doxorubicin. Eur J Cancer Clin Oncol 19: 411–418, 1983

    PubMed  Google Scholar 

  11. Wittes RE, Marsoni S, Simon R, Leyland-Jones B: The phase If trial. Cancer Treat Rep 69: 1235–1239, 1985

    PubMed  Google Scholar 

  12. Leitner SP, Casper ES, Hakes TB, Kaufman RJ, Winn RJ, Scoppetuolo M, Raymond V, Geller NL, Young CW: Phase II trial of 4′-deoxydoxorubicin in patients with advanced breast cancer. Cancer Treat Rep 69: 1319–1320, 1985

    PubMed  Google Scholar 

  13. Braich TA, Salmon SE, Robertone A, Alberts DS, Jones SE, Miller TP, Garewal HS: Phase II trial of esorubicin (4′-deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma. Invest New Drugs 4: 269–274, 1986

    PubMed  Google Scholar 

  14. Rankin EM, Knight RK, Rubens RD: A phase II study of 4-deoxydoxorubicin in advanced breast cancer. Eur J Cancer Clin Oncol 23: 1079–1080, 1987

    PubMed  Google Scholar 

  15. Carlson RW, Billigham ME, Kohler M, Johnson FD, Doroshow JH, Torti FM: Esorubicin in refractory metastatic carcinoma of the breast: A Northern California Oncology Group study. Cancer Treat Rep 71: 427–428, 1987

    PubMed  Google Scholar 

  16. Bonfante V, Rossi A, Brambilla C, Ferrari L, Villani F, Comazzi R, Crippa F, Monfardini S, Bonadonna G: Comparative activity and toxicity of adriamycin (ADM) and new anthracycline analogs in advanced breast cancer. Proc AACR (Abstract) 26: 165, 1985

    Google Scholar 

  17. Muss HB, Van Echo DA, Korzun AH, Henderson IC, Campbell T, Vogelzang N, Rice MA, Wood W: Deoxydoxorubicin (DxDx) for advanced breast cancer: A phase II study of the CALGB. Breast Cancer Res Treat (Abstract), 8: 110, 1986

    Google Scholar 

  18. Brambilla C, DeLena M, Rossi A, Valagussa P, Bonadonna G: Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J i: 801–804, 1976

    Google Scholar 

  19. Carbone PP, Bauer M, Band P, Tormey D: Chemotherapy of disseminated breast cancer: Current status and prospects. Cancer 39: 2916–2922, 1977

    PubMed  Google Scholar 

  20. Bull JM, Tormey DC, Li S-H, Carbone PP, Falkson G, Blom J, Perlin E, Simon R: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657, 1978

    PubMed  Google Scholar 

  21. Brunner KW, Sonntag RW, Martz G, Senn HJ, Obrecht P, Alberto P: A controlled study in the use of combined drug therapy for metastatic breast cancer. Cancer 36: 1208–1219, 1975

    PubMed  Google Scholar 

  22. Samal BA, Brooks SC, Cummings G, Franco L, Hire EA, Martino S, Singhakowinta A, Vaitkevicius VK: Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy. Cancer 46: 2925–2927, 1980

    PubMed  Google Scholar 

  23. Ahmann DL, Schaid DJ, Bisel HF, Hahn RG, Edmonson JH, Ingle JN: The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. Clin Oncol 5: 1928–1932, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Hematology and Oncology, Wayne State University/Harper-Grace Hospitals, P.O. Box 02188, 48202-0188, Detroit, Michigan, USA

    Sitvana Martino (Associate Professor of Medicine), Bohumil A. Samal, Bruce Redman, Lawrence Flaherty, Michael Kraut, Michael Simon & Manuel Valdivieso

Authors
  1. Sitvana Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bohumil A. Samal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruce Redman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lawrence Flaherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Kraut
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manuel Valdivieso
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martino, S., Samal, B.A., Redman, B. et al. Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer. Breast Cancer Res Tr 17, 139–143 (1990). https://doi.org/10.1007/BF01806294

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806294

Key words

Search

Navigation